Who this study may be for
Age
Adults 18 years and older.
Diagnosis
People with advanced non-small cell lung cancer (NSCLC).
Current status
Disease that has progressed after standard treatment and still needs another treatment option.
Medication history
The study team reviews current and prior anticancer medicines, including chemotherapy, during screening.
Study goals
The primary goal is to evaluate whether the investigational combination therapy can slow or stop cancer growth in participants whose disease has progressed after standard treatment.
Researchers are also studying the safety profile of the therapy, how participants tolerate treatment over time, and how the therapy affects quality of life.
The screening process
Medical history review
The study team reviews your diagnosis, prior treatments, and current health to determine whether the study criteria are a match.
Baseline assessments
Screening includes blood tests, imaging scans, and a physical exam to establish a starting point before treatment begins.
Informed consent
Before any study procedures begin, the team explains the study in detail and answers your questions. You decide whether to participate.
What happens during treatment
Participants receive the investigational therapy at the research site according to a defined schedule. Visits typically occur every two to three weeks during the active treatment period.
At each visit, the study team performs assessments to monitor your health and the therapy's effects. Imaging scans are scheduled at regular intervals to evaluate how the cancer is responding.
Questions about eligibility?
The study team can help determine whether this study may be appropriate for your situation.
See frequently asked questions